Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
Inventiva S A : Information financière du 1er semestre 2020 | Zone bourse
04:30pm, Monday, 06'th Jul 2020Information financière du 1er semestre 2020
04:30pm, Monday, 06'th Jul 2020
Trésorerie et équivalents de trésorerie à 52,2 M€ au 30 juin 2020
Daix (France), le 6 juillet 2020 - Inventiva (Euronext : IVA), société biopharmaceutique spécialisée dans le déve
Akero Therapeutics Announces Proposed Public Offering of Common Stock
11:00am, Monday, 06'th Jul 2020
Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall h
A la suite des effets plus importants que prévus concernant la réduction de la stéatose lors de l'étude de Phase IIb NATIVE dans la NASH, le...
Corcept's Phase 3 Trial, And Other News: The Good, Bad And Ugly Of Biopharma
06:40am, Sunday, 05'th Jul 2020
Corcept starts its phase 3 pancreatic cancer trial. Ultragenyx gets approval for Dojolvi. Akero posts strong NASH data.
Akero Therapeutics (NASDAQ:AKRO) Shares Gap Up on Analyst Upgrade
01:16am, Saturday, 04'th Jul 2020
Shares of Akero Therapeutics (NASDAQ:AKRO) gapped up before the market opened on Thursday after JPMorgan Chase & Co. raised their price target on the stock from $28.00 to $41.00. The stock had previou
Squarepoint Ops LLC Sells 39,110 Shares of Akero Therapeutics (NASDAQ:AKRO)
07:31am, Friday, 03'rd Jul 2020
Squarepoint Ops LLC trimmed its stake in Akero Therapeutics (NASDAQ:AKRO) by 66.8% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,3
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) * AbbVie Inc (NYSE: ABBV) * ADC Therapeutics SA (NYSE
89bio (ETNB) Receives a Buy from Oppenheimer - Markets
10:56am, Thursday, 02'nd Jul 2020
Oppenheimer analyst Jay Olson maintained a Buy rating on 89bio (ETNB – Research Report) today and set a price target
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
12:00am, Thursday, 02'nd Jul 2020
Regulatory News: ABIONYX Pharma (Paris:ABNX): Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total vo
Akero Therapeutics (AKRO) Reports Biopsy Data and Safety/Tolerability for 16-Week Phase 2a Study in NASH Patients - Slideshow
06:13pm, Wednesday, 01'st Jul 2020
The following slide deck was published by Akero Therapeutics, Inc. in conjunction with this event.
Akero Therapeutics (AKRO) Jumps: Stock Rises 8.9%
01:03pm, Wednesday, 01'st Jul 2020
Akero Therapeutics (AKRO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes
12:12pm, Wednesday, 01'st Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) * ADC Therapeutics SA (NYSE: ADCT) * Akebia Therapeu
Akero Therapeutics (NASDAQ:AKRO) PT Raised to $51.00 at Canaccord Genuity
11:40am, Wednesday, 01'st Jul 2020
Akero Therapeutics (NASDAQ:AKRO) had its price target boosted by equities research analysts at Canaccord Genuity from $36.00 to $51.00 in a report released on Wednesday, The Fly reports. The brokerage
Jefferies Financial Group Raises Akero Therapeutics (NASDAQ:AKRO) Price Target to $48.00
11:07am, Wednesday, 01'st Jul 2020
Akero Therapeutics (NASDAQ:AKRO) had its price objective lifted by research analysts at Jefferies Financial Group from $31.00 to $48.00 in a research report issued to clients and investors on Wednesda
